Relief Therapeutics Holding AG (RLFTF)

[Penny Monster 01]

T2Bacteria Panel
Species identification in hours instead of days, including deadly ESKAPE pathogens
The T2Bacteria® Panel is the first and only FDA-cleared and CE-marked test to identify sepsis-causing bacteria directly from whole blood without the wait for blood culture.

T2Bacteria identifies:
50% of all bacterial bloodstream infections1
70% of all blood culture species in the emergency department2
92% of deadly ESKAPE pathogens3
Species identification in just hours: The commercially available T2Bacteria Panel provides species identification in 3 to 5 hours while the current standard of care takes 1 to 5 days or more.1 One T2Bacteria test result detects the equivalent of three sets of blood cultures for many species.2

Improved time to targeted therapy: By incorporating the Panel as part of the sepsis bundle, physicians can get more patients on the right therapy faster, thus improving empiric therapy protocols, potentially preventing the progression of sepsis, while increasing the chances of both patient survival and recovery.

Game-changing performance: In the T2Bacteria pivotal clinical trial1 conducted in 11 U.S. centers with 1,427 patients, investigators demonstrated:

Highly accurate results – identifying 3 times more infections than the paired blood culture draw
Positive and negative results more than 2 days faster than blood culture
Opportunities to de-escalate therapy and improve time to targeted therapy by days
No detection interference when patients are on antibiotic therapy, a well-known limitation of blood culture